贝伐单抗联合替莫唑胺对复发恶性脑胶质瘤患者疾病控制率及生存周期的影响

Effect of Bevacizumab Combined with Temozolomide on Disease Control Rate and Survival Cycle in Patients with Recurrent Malignant Brain Glioma

目的:探究贝伐单抗联合替莫唑胺对复发恶性脑胶质瘤患者疾病控制率及生存周期的影响。方法:选取2011年12月—2015年12月我院复发恶性脑胶质瘤患者84例,依据随机数字表法分为两组,各42例。对照组采取贝伐单抗(5 mg/kg,静注,2周/次)治疗,于此基础上观察组联合替莫唑胺(150 mg/m^2,qd,口服,连用7 d,停用7 d)治疗。比较两组疾病控制率、中位无进展生存时间、6个月无进展生存率、毒副反应发生情况,并比较两组治疗前、治疗后6个月生活质量评分。结果:观察组疾病控制率高于对照组,差异有统计学意义(P <0.05);观察组中位无进展生存时间、6个月无进展生存率均高于对照组,差异有统计学意义(P <0.05);治疗前两组躯体疼痛、生理功能、情感职能、精神状态、社会功能等生活质量评分比较差异无统计学意义(P> 0.05),治疗后6个月观察组上述生活质量各维度评分均较对照组提高,差异有统计学意义(P <0.05);两组毒副反应发生率比较,差异无统计学意义(P> 0.05)。结论:予以复发恶性脑胶质瘤患者贝伐单抗联合替莫唑胺治疗可显著提高疾病控制率,延长患者生存周期,提高生活质量,且安全性高。

Objective:To investigate the effect of bevacizumab combined with temozolomide on disease control rate and survival cycle in patients with recurrent malignant brain glioma.Methods:84 patients with recurrent malignant brain glioma from December 2011 to December 2015 were selected and randomly divided into two groups,42 cases each.The patients in the control group were treated with bevacizumab(5 mg/kg,intravenous injection,2 weeks/time).On this basis,the patients in the observation group were treated with temozolomide(150 mg/m2,qd,oral administration for 7 days,no treatment with temozolomide for 7 days).The disease control rate,median progressionfree survival time,6-month progression-free survival rate and toxicity and other side effects were compared between the two groups,and the scores of quality of life before treatment and 6 months after treatment were compared between the two groups.Results:The disease control rate in the observation group was higher than that in the control group,and the difference was statistically significant(P<0.05).The median progression-free survival time and 6-month progression-free survival rate in the observation group were higher than those in the control group,and the differences were statistically significant(P<0.05).There was no statistically significant difference in the scores of quality of life such as physical pain,physiological function,emotional function,mental state and social function between the two groups before the treatment(P>0.05).After 6 months of treatment,the scores of quality of life in different dimensions in the observation group were higher than those in the control group(P<0.05).Conclusion:Bevacizumab combined with temozolomide can significantly improve the disease control rate,prolong patient’s life cycle and improve the quality of life in the treatment of recurrent malignant brain glioma,and has high safety.